

## REVIEW ARTICLE

## THE CHANGING FACE OF CLINICAL TRIALS

Jeffrey M. Drazen, M.D., David P. Harrington, Ph.D., John J.V. McMurray, M.D., James H. Ware, Ph.D.,  
and Janet Woodcock, M.D., *Editors*

## Pragmatic Trials

Ian Ford, Ph.D., and John Norrie, M.Sc.

From the Robertson Centre for Biostatistics, University of Glasgow, Glasgow (I.F.), and the Centre for Healthcare Randomised Trials, Health Services Research Unit, University of Aberdeen, Aberdeen (J.N.) — both in the United Kingdom. Address reprint requests to Dr. Ford at the Robertson Centre for Biostatistics, University of Glasgow, Level 11, Boyd Orr Bldg., Glasgow G12 8QQ, United Kingdom, or at ian.ford@glasgow.ac.uk.

N Engl J Med 2016;375:454-63.

DOI: 10.1056/NEJMra1510059

Copyright © 2016 Massachusetts Medical Society.

PRAGMATISM IN CLINICAL TRIALS AROSE FROM CONCERNS THAT MANY trials did not adequately inform practice because they were optimized to determine efficacy.<sup>1</sup> Because such trials were performed with relatively small samples at sites with experienced investigators and highly selected participants, they could be overestimating benefits and underestimating harm. This led to the belief that more pragmatic trials, designed to show the real-world effectiveness of the intervention in broad patient groups, were required. Medical researchers, both academic and commercial, must deliver health care innovations (drugs, devices, or other interventions) that are safe, beneficial, and cost-effective, and they must identify the subgroups for whom the innovation will provide the greatest benefit relative to risk. A broad view of an intervention, including approaches to improve its effectiveness, is critical. An ideal trial includes a population that is relevant for the intervention, a control group treated with an acceptable standard of care, and outcomes that are meaningful, and it must be conducted and analyzed at a high standard of quality. Pragmatic trials frequently include complex interventions, sometimes consisting of several interacting components<sup>2</sup> and often involving the skills and experience of one or more health care professionals to deliver the intervention — for example, surgeons, physiotherapists, or cognitive behavioral therapists.

In this article, we do not provide a definitive exposition of the methods used for pragmatic trials. Rather, we explore the contexts in which a pragmatic design is most and least attractive and identify the strengths and limitations of — and challenges in implementing — pragmatic trials.

## WHAT IS A PRAGMATIC TRIAL?

Schwartz and Lellouch<sup>1</sup> proposed a distinction between explanatory trials, which confirm a physiological or clinical hypothesis, and pragmatic trials, which inform a clinical or policy decision by providing evidence for adoption of the intervention into real-world clinical practice. The original PRECIS (Pragmatic–Explanatory Continuum Indicator Summary) tool<sup>3</sup> attempted to clarify the concept of pragmatism and provided a guide, scoring system, and graphical representation of the pragmatic features of a trial. Features included the recruitment of investigators and participants, the intervention and its delivery, follow-up, and the determination and analysis of outcomes. Many trials could be deemed to be pragmatic with regard to at least one of these dimensions, but few are truly pragmatic on all dimensions. Pragmatism has been discussed widely,<sup>4-20</sup> and a special issue of *Clinical Trials* had 12 articles focused on ethical and regulatory issues in pragmatic trials.<sup>21</sup> The requirements for pragmatism were loosened substantially in PRECIS-2,<sup>22</sup> and a pragmatic extension to the CONSORT statement has been proposed.<sup>23</sup> Key dimen-

**Table 1.** Nine Dimensions for Assessing the Level of Pragmatism in a Trial, as Proposed in the Pragmatic–Explanatory Continuum Indicator Summary 2 (PRECIS-2) Tool.\*

Dimension	Assessment of Pragmatism
<b>Recruitment of investigators and participants</b>	
Eligibility	To what extent are the participants in the trial similar to patients who would receive this intervention if it was part of usual care?
Recruitment	How much extra effort is made to recruit participants over and above what would be used in the usual care setting to engage with patients?
Setting	How different are the settings of the trial from the usual care setting?
<b>The intervention and its delivery within the trial</b>	
Organization	How different are the resources, provider expertise, and organization of care delivery in the intervention group of the trial from those available in usual care?
Flexibility in delivery	How different is the flexibility in how the intervention is delivered from the flexibility anticipated in usual care?
Flexibility in adherence	How different is the flexibility in how participants are monitored and encouraged to adhere to the intervention from the flexibility anticipated in usual care?
<b>The nature of follow-up</b>	
Follow-up	How different is the intensity of measurement and the follow-up of participants in the trial from the typical follow-up in usual care?
<b>The nature, determination, and analysis of outcomes</b>	
Primary outcome	To what extent is the primary outcome of the trial directly relevant to participants?
Primary analysis	To what extent are all data included in the analysis of the primary outcome?

\* Information in the table is adapted from Loudon et al.<sup>22</sup>

sions for assessing the degree of trial pragmatism, following PRECIS-2, are provided in Table 1. The trials that are used as pragmatic exemplars throughout this article are summarized in Table 2.

#### CHALLENGES TO PRAGMATISM AND POTENTIAL SOLUTIONS

##### RECRUITMENT OF STUDY PARTICIPANTS

Pragmatic trials require that participants be similar to patients who would receive the intervention if it became usual care, which may be unknown for new interventions. Participation in trials has fallen over time; for example, among persons without established disease, a lower than 10% rate of response to a screening invitation is common. The fact that volunteers participating in certain types of trials are often healthier than persons in the general population (the “healthy-volunteer effect”) and competing recruitment

from other trials, particularly in academic centers, undermine attempts to achieve generalizability. Financial incentives associated with recruitment to industry trials can substantially affect recruitment to less-well-funded academic trials. Minimization of inclusion and exclusion criteria and reduction in the number and complexity of study visits, study procedures, and questionnaire burden are important but are likely to be only partial measures to increase participation in trials.

In this regard, the development of large, simple trials (e.g., the Heart Protection Study<sup>24</sup> and the Corticosteroid Randomization after Significant Head Injury [CRASH] trial<sup>25</sup>) has been important. The Thrombus Aspiration in ST-Elevation Myocardial Infarction in Scandinavia (TASTE) trial,<sup>26</sup> a trial of thrombus aspiration versus usual best care before percutaneous coronary intervention, involved 7244 participants

**Table 2. Exemplar Trials and Their Main Pragmatic Features.**

Trial	Recruitment of Investigators and Participants	Intervention and Its Delivery	Follow-up	Determination and Analysis of Outcomes
Thrombus Aspiration in ST-Elevation Myocardial Infarction in Scandinavia (TASTE)	Registry-based randomized, controlled trial; participants underwent randomization within an existing registry for coronary angiography and angioplasty; high level of participation (approximately 60% of eligible participants); individual consent required for the trial; initial oral consent confirmed in writing within 24 hr	Intervention was thrombus aspiration or usual best care before percutaneous coronary intervention	No follow-up visits; no trial-specific validation of national registry procedures or outcomes; sample size increased because of a low event rate	Data and outcomes extracted from registry database and record linkage to a national discharge registry; no loss to follow-up
Post-Myocardial Infarction Free Rx Event and Economic Evaluation (MI FREEE)	Cluster design, no individual participant consent required; controlled policy trial (“value-based insurance design” or “evidence-based plan design”); excluded patients whose medications were already fully covered	Insurance-plan sponsors were randomly assigned to usual or full prescription coverage; no special clinical interventions, all drugs within a class considered; study administered by commercial insurer	Participants followed up remotely; follow-up changed from a minimum of 1 yr to minimum of 3 mo	Outcomes determined algorithmically from health care databases; economic evaluation; no patient-reported outcomes (consistent with no consent) or safety reporting (increased adherence could mean more side effects)
Antimicrobial catheters for reduction of symptomatic urinary tract infection (UTI) in adults requiring short-term catheterization in hospital	Individually randomized trial of three catheter types in elective and emergency contexts; retrospective consent required for emergency cases; heterogeneity of hospitals, specialties, and surgical procedures	Open design with active control; impractical to blind catheter assignments; 50% of participants who underwent emergency catheterization did not confirm consent; 4% of participants did not get a catheter, and another 4% of participants did not get the catheter to which they had been randomly assigned	Primary outcome was symptomatic catheter-associated UTI; secondary outcome was confirmed catheter-associated UTI; hospital-based and community-based follow-up (for 6 wk after catheter removal)	No differences found, in contrast to results of a meta-analysis of generally small, single-center, explanatory, randomized, controlled trials (differences may have been due to publication bias, the use of highly select populations, or the use of laboratory-based outcomes)
Corticosteroid Randomization after Significant Head Injury (CRASH)	Individually randomized; placebo controlled	No consent required (emergency surgery), with local variations; fixed dose of glucocorticoid to simplify; any patient eligible if treating doctor uncertain about giving glucocorticoids	Very simple; pragmatic outcome of all-cause mortality; two-page case-report form; no record of concomitant medications or procedures	Approximately 10,000 participants in 239 hospitals in 49 countries underwent randomization; follow-up rate >99%; adherence, 98%; 99% of participants received full dose; study terminated early because of excess deaths associated with glucocorticoid treatment; had immediate effect on practice

<p>A Stop Smoking in Schools Trial (ASSIST)</p>	<p>Cluster, public health, randomized, controlled trial involving 59 schools (10,730 pupils); 127 of 233 schools expressed interest; 66 schools randomly selected from 113 agreeing to participate; individual consent required for follow-up in a vulnerable group</p>	<p>Complex intervention for smoking prevention in adolescence; smoking advice delivered by consensus-identified class “leaders”; randomized at school level, outcomes aggregated at school level (year group)</p>	<p>Saliva samples collected for cotinine measurement</p>	<p>Analysis complicated; three-tier hierarchical repeated-measures model; high response rates (&gt;90%); low proportion withdrawn by parents (at start) or refused to participate (&lt;5%)</p>
<p>High-Sensitivity Troponin in the Evaluation of Patients With Acute Coronary Syndrome (High-STEACS)</p>	<p>Stepped-wedge, diagnostic policy trial; hospitals randomly assigned to use standard troponin I assay or high-sensitivity troponin I assay for the diagnosis of myocardial infarction; no individual consent for trial</p>	<p>New assay introduced into normal care pathways; hospitals used older assay for all admissions for chest pain until their randomly assigned switch time, after which the new assay was used for all admissions for chest pain</p>	<p>No trial-specific visits; main outcome, cardiovascular death or recurrent myocardial infarction at 1 yr; consent required for samples for explanatory laboratory-based substudy</p>	<p>Trial outcomes determined by linkage to national electronic databases of hospital discharge summaries, deaths, and other medical records; outcome to be analyzed using a “safe harbor” approach</p>
<p>Initial Antidepressant Choice in Primary Care</p>	<p>Head-to-head “policy” randomized, controlled trial assessing the effectiveness and cost of fluoxetine vs. tricyclic antidepressants as first-line therapy for depression, to study the consequences of initial antidepressant choice under usual care conditions</p>	<p>Open trial to preserve usual care approach; coexisting conditions or severity of depression not exclusion criteria; 6% ineligible, 7% declined; no restriction on doses of study or concomitant drugs</p>	<p>Follow-up assessments at 1, 3, 6, 9, 12, 18, and 24 mo after randomization; interviewers unaware of the assigned intervention</p>	<p>Multiple outcomes: clinical and cost-effectiveness; adverse effects; quality of life; no restrictions on crossovers or discontinuations; results may not be generalizable to different health care systems</p>
<p>Leukotriene Antagonists as First-Line or Add-on Asthma-Controller Therapy</p>	<p>Primary care, head-to-head randomized, controlled trial; equivalence design</p>	<p>Open-label, pragmatic trial comparing technologies; choice of drug within a class left to local preference; approximately 6% postrandomization exclusions, perhaps unusual in a pragmatic trial</p>	<p>Patient heterogeneity; blinding; no placebo; poor adherence; treatment crossovers</p>	<p>Intention-to-treat analysis with per-protocol as backup; multiple imputation used for missing data; study lacked power because of greater variability in outcome than expected (more heterogeneous population, lower adherence, crossovers)</p>

and had a primary end point of 30-day all-cause mortality. The trial used a national registry (the Swedish Coronary Angiography and Angioplasty Registry) and achieved high participation because of the simple design and absence of a need for additional follow-up. The trial did not show a differential response to the treatments.

Informed consent is a barrier to unselected participant recruitment. To guarantee that everyone who is eligible is included, this requirement would need to be waived. In some contexts, it is possible — subject to ethics approval — to conduct trials without consent or with modified consent. In the Post-Myocardial Infarction Free Rx Event and Economic Evaluation (MI FREEE) cluster-based trial,<sup>27</sup> 2980 sponsors of health care plans were randomly assigned to provide either usual prescription coverage or full prescription coverage, with a primary end point of a first major vascular event or revascularization among patients. In this trial, which required consent from plan sponsors but not from patients, the elimination of copayments for drugs that were prescribed after myocardial infarction was not associated with a significantly lower rate of the primary outcome. A trial involving 6394 participants was conducted to assess the effect of emergency short-term use of antiseptic-coated versus antibiotic-impregnated versus plain latex catheters with regard to the primary outcome of the incidence of symptomatic urinary tract infection for which an antibiotic was prescribed within 6 weeks.<sup>28</sup> After the initial admission, prospective consent was obtained according to usual practice from participants who were undergoing elective procedures, and retrospective consent was obtained in cases of emergency admissions, thus maximizing the generalizability of the findings. Routine use of antibiotic-impregnated or antiseptic-coated catheters was not supported by the results of this trial.

In the CRASH trial, more than 10,000 patients with head injury and impaired consciousness underwent randomization to determine whether glucocorticoids, as compared with placebo, affected the rates of death and neurologic disability. The trial was stopped early because of evidence that glucocorticoid treatment was associated with higher mortality.<sup>25</sup> In CRASH, the nature of consent depended on local ethics decisions, with consent waivers or consent from a

legal representative being allowed in some cases. If a trial neither interferes with normal clinical care nor adds nonstandard activities or data collection, the objection to waiving consent is reduced. In low-risk contexts, random assignment of patients to alternative established treatments may be possible without obtaining consent,<sup>19</sup> as might a trial with a cluster design in which physicians are randomly assigned to prescribe only one of the alternative treatments.

Cluster randomization, as in MI FREEE,<sup>27</sup> which involves groups of patients (in the same health care facility) who are randomly assigned to the same intervention, is popular in pragmatic trials. Cluster-cluster trials assess outcomes aggregated at the cluster level, whereas cluster-individual trials assess individual-level outcomes. Cluster-cluster trials offer greater possibilities of waiving the need for consent at the cluster-member level.<sup>21,29</sup> Cluster-individual trials offer the option of waiving consent for the intervention, with consent obtained only for participant follow-up. This approach was implemented in A Stop Smoking in Schools Trial (ASSIST), a cluster-randomized trial of a high school smoking-prevention intervention with a primary outcome of smoking in the past week.<sup>30</sup> The results of the trial suggested that the ASSIST intervention could lead to a reduction in adolescent smoking prevalence of public-health importance.

The ongoing High-Sensitivity Troponin in the Evaluation of Patients with Acute Coronary Syndrome (High-STEACS) trial<sup>31</sup> is investigating the clinical implications of a high-sensitivity troponin I biomarker for the diagnosis of myocardial infarction, with a primary outcome of cardiovascular death or recurrent myocardial infarction within 12 months after admission. Like MI FREEE, this is a trial of policy change. It uses a stepped-wedge cluster design<sup>32</sup> in which all sites transition from the control to the active intervention but with randomized assignments to the timing of transition, with some sites assigning patients before others. Such trials assessing a policy that is going to be implemented in any event arguably offer the greatest potential for pragmatic trials, since they require no individual consent while allowing for some degree of control of ecologic changes in care that may be happening simultaneously.

In summary, pragmatic trials face some

unique challenges along with many of the same challenges that are associated with traditional explanatory trials. Strategies to enhance recruitment have been proposed.<sup>33</sup> When appropriate, various forms of cluster randomization offer advantages and may help avoid the need for informed consent. Disease registries provide cohorts of patients who have already given consent for registry inclusion, which facilitates recruitment and follow-up. A related approach is the cohort multiple-randomized design,<sup>34</sup> in which a cohort of participants is recruited and consent is obtained for follow-up and possible recruitment into trials of new treatments versus standard care. In any particular trial of this type, additional consent is obtained only from participants who are randomly assigned to the new intervention, which reduces the concerns of participants who have been randomly assigned to usual care.

#### RECRUITMENT OF INVESTIGATORS

Trials need investigators to take responsibility for recruitment, treatment, and follow-up of participants. Many health care professionals outside of academic centers do not participate in clinical trials, in part because of the time pressures associated with their clinical duties or because they do not consider research to be a key component of their job. Hence, the investigators involved in a trial will often not encompass the heterogeneity of practice that is present in usual care. In contrast, investigators across Sweden who were contributing to a national quality registry were included in the TASTE trial.<sup>26</sup>

Good trials include a variety of investigators with a representative mix of experience appropriate to the intervention under study. The trial of short-term use of antiseptic-coated versus antibiotic-impregnated versus plain latex catheters<sup>28</sup> made substantial efforts to include a heterogeneous group of hospitals, specialists, and surgical procedures. Despite these examples, this is a dimension on which many trials fail the pragmatism test. A pragmatic approach is easier when an intervention is implemented at a group level rather than at an individual level — this is one reason that pragmatic trials commonly incorporate cluster randomization. In ASSIST, only 113 of 233 possible schools (48%) expressed an interest in participating in the trial.<sup>30</sup> The percentage of potential clusters agreeing to take part will vary

according to the trial context. A trial that is run by an overarching authority may achieve much higher participation. For example, a hospital could insist on the full involvement of all wards in a trial of approaches to infection control.

However, the wrong type of heterogeneity can be harmful. For example, if participants in many countries with poorly developed health care systems are enrolled in a trial assessing the effect that primary care nurses monitoring patients with heart failure have on reducing emergency admissions for heart failure, the trial would not inform the implementation of a role for such nurses in a developed health care system. Likewise, if an intervention involves substantial technical expertise, then that intervention should be delivered by practitioners with an adequate throughput of patients to enable them to maintain their levels of expertise. This is particularly true in surgical trials, in which complex surgery is increasingly delivered in high-volume centers. This creates a conflict in the design of pragmatic trials. Should we conduct a trial in the health care environment that currently exists or in a context representing the health care environment that is likely to exist in the future in the relevant specialist area?

If heterogeneity in responses to the intervention is likely, a trial must be large enough to permit an understanding of that heterogeneity; this may require a substantial increase in sample size to detect a treatment-by-subgroup interaction. Often, there will be power to detect treatment-by-subgroup interactions only in large meta-analyses conducted at the individual-patient level.

Establishing a critical mass for efficient trial conduct is crucial. Providing incentives to investigators is important in the face of increasing demand to deliver clinical services more efficiently, since research takes additional time beyond standard clinical care. The development of clinical networks and establishment of disease-specific research communities is one way forward. Another would be to give credit to health professionals for research as a key component of professional work plans. In the United Kingdom, these approaches, along with the creation of a national network of clinical-trial units that have been registered as fit-for-purpose, has improved the recruitment and retention of clinical investigators and methodologists working together to

deliver trials by avoiding the common approach of setting up a network to deliver a single trial that is then not reused for future trials.<sup>35</sup>

#### THE INTERVENTION AND ITS DELIVERY WITHIN THE TRIAL

A trial with blinded interventions is not fully pragmatic. In pragmatic trials, the randomly assigned group is commonly not masked. Efforts that are made to minimize biases in open trials include focusing outcomes on major events, such as death and emergency hospital admissions. This approach has been used in the Prospective Randomized Open Blinded End-point (PROBE) trials,<sup>36</sup> such as the Anglo-Scandinavian Cardiac Outcomes Trial–Blood Pressure Lowering Arm (ASCOT-BPLA) trial<sup>37</sup> and the Systolic Blood Pressure Intervention Trial (SPRINT)<sup>38</sup> of the effect on cardiovascular events of different strategies for lowering blood pressure. However, the reporting of nonserious adverse events, reasons for treatment discontinuation, and many patient-reported outcomes are subject to greater degrees of bias in open trials, which affects the quality of the trial. The Initial Antidepressant Choice in Primary Care trial,<sup>39</sup> a policy trial of fluoxetine versus tricyclic drugs as first-line therapy for depression, assessed the consequences of the initial choice of an antidepressant agent under usual care conditions; adverse events were a main outcome, and the open nature of the trial could have compromised the integrity of this outcome. In the trial, clinical and quality-of-life outcomes and overall treatment costs provided no clear guidance regarding the initial selection of fluoxetine or tricyclic drugs. The CRASH trial involved a placebo control and blinding; nonetheless, it had many pragmatic elements. In many situations, the need to avoid reporting bias will override purist pragmatic considerations, making blinding the optimal approach. In complex intervention trials, in which blinding the intervention is often impossible, it is usually possible to blind the assessment of outcomes.<sup>36</sup> In any trial, the advantages and disadvantages of blinding must be considered; blinding is particularly important when the reporting of key end points or safety events could be biased in an open trial.

In pragmatic designs, the intervention should be delivered as in normal practice, by staff with typical experience and with the use of routinely

available equipment. The MI FREEE trial<sup>27</sup> tested a treatment policy by assessing drugs within a class, but decisions with regard to the specific drug and dose within that class were left to the investigators. (A pragmatic trial often investigates a general approach to treatment rather than dictating the specific details of that approach.) The degree of support for participants in treatment persistence (i.e., in ensuring that participants continue to undergo the treatment) can influence outcome. Traditional trials rely on study visits that involve discussion of adherence and recording of laboratory tests for safety, as well as other investigations beyond normal practice. A trial that is dominated by poor adherence to the protocol or poor delivery of the intervention is of limited use. Ideally, a balance would be achieved, and both the intervention and its mode of delivery would be taken into consideration. Investigators should be given basic advice on how to achieve good outcomes for participants, as well as reasonable levels of training in new interventions within the constraints of the environment in which the trial is conducted.

#### THE NATURE OF TRIAL FOLLOW-UP

The unobtrusive collection of trial outcomes is attractive; it reduces the burden on the participants and investigators without introducing artificial aspects to follow-up. Such a strategy is most feasible in health care systems with reliable and accessible electronic health records that capture the events of interest. This might be achievable where there is a unified electronic health care record, but it is at present challenging in many countries. The High-STEACS trial,<sup>31</sup> which has no trial-specific data-collection visits at all, illustrates the potential of this approach. Likewise, MI FREEE<sup>27</sup> followed participants through a health care database, with outcomes determined algorithmically. Linkage of trial records to routinely collected health records in the West of Scotland Coronary Prevention Study (WOSCOPS)<sup>40-43</sup> illustrates the benefits of using health records to identify serious adverse events and that their use might replace traditional within-trial end-point determination, as well as in evaluating long-term poststudy safety, efficacy, and cost-effectiveness. An attractive alternative to trials in which electronic health records are used can be found in trials of alternative interventions involving pa-

tients who are already enrolled in disease-specific or intervention-specific registries that incorporate detailed patient phenotypes and long-term follow-up data. This framework provides an efficient and low-cost opportunity for conducting pragmatic trials (e.g., the TASTE trial<sup>26</sup>).

#### THE NATURE, DETERMINATION, AND ANALYSIS OF TRIAL OUTCOMES

Pragmatic end points should be important to patients — for example, major life events (e.g., death or emergency hospital admission). Pragmatic trials are also often large, identify limited treatment effects, and assess the safety of under-investigated interventions in unselected populations. They are also often simple and minimize trial procedures and data-collection requirements. The CRASH trial<sup>29</sup> achieved a high degree of simplicity with a two-page case-report form. The catheter trial<sup>28</sup> had a primary outcome of symptomatic catheter-associated urinary tract infection up to 6 weeks after hospital discharge, rather than laboratory-confirmed infections in the hospital, which emphasized the importance of health resource use over mechanistic outcomes.

Symptoms, disability, and quality of life are commonly key outcomes in pragmatic trials. Unlike major life events, signs and symptoms and quality-of-life measures are seldom recorded consistently in routine practice and require patient visits or completion of questionnaires. Pragmatic trials often use mailed questionnaires or Web-based forms to avoid the need for study visits. Such methods reduce costs but can lead to substantial amounts of missing data, which creates challenges for analysis and interpretation. Offering participants alternative methods of providing responses, including mobile phones and other handheld devices, might increase response rates. Research into shorter, effective patient-reported outcome questionnaires continues.<sup>44</sup> The ASSIST trial<sup>30</sup> achieved a higher than 90% rate of return of self-reported data, an unusually high level. In mental health and other areas in which many outcomes are based on questionnaires, direct follow-up is difficult to avoid. For example, the Initial Antidepressant Choice in Primary Care trial<sup>37</sup> (a trial with an otherwise pragmatic design) had study visits at 1, 3, 6, 9, 12, 18, and 24 months after randomization. The main results of the trial were based on the first three

study visits, and 91% of these visits were completed. Quality-of-life outcomes play an important role in cost-effectiveness analyses, which are a common feature of pragmatic trials, as illustrated in MI FREEE<sup>27</sup> and the Initial Antidepressant Choice in Primary Care trial of fluoxetine versus tricyclic drugs.<sup>37</sup> Clearly, quality-of-life outcomes cannot be collected in a no-consent trial, such as MI FREEE, or in trials with follow-up within a registry or electronic health system, such as High-STEACS<sup>31</sup> and TASTE,<sup>26</sup> unless they are routinely recorded.

Pragmatic trials can provide long-term safety data for unselected populations. However, there are challenges in interpreting safety data, which are often self-reported or subject to delays in availability, incompleteness, and coding variability associated with national registries. Explanatory trials can also present interpretational challenges with respect to adverse events, because data on events are sometimes not collected after discontinuation of the randomly assigned treatment, which introduces bias into statistical analyses.

It has been argued that pragmatic outcomes should not need adjudication. We believe this is a quality issue rather than a pragmatic issue. If the quality and consistency of outcome ascertainment can be improved by adjudication without affecting normal patient care, then surely that is desirable.

#### DISCUSSION

Drug development involves the cautious introduction of a new substance into human participants, with gradual evaluation in patients who have the relevant disease, in order to evaluate safety, early evidence of efficacy, and appropriate doses for future evaluation. The development of nondrug interventions should, but often do not, involve proof-of-concept or pilot studies to tailor the intervention and evaluate its acceptability. Many such interventions also require selection of a dose, such as duration and intensity of physiotherapy or physical training. These trials by their nature could be, but need not be, pragmatic, because they involve careful refinement of the intervention and assessment of its potential value in clinical practice.

It is only after phase 3 drug trials that we

have any real understanding of whether the treatment is beneficial, who might benefit most, the potential adverse effects, and the most cost-effective implementation. The ideal time to perform a pragmatic trial would be during the implementation stage of a complex intervention or the postmarketing phase of drug evaluation, to help provide an understanding of what the effect of introducing the new technology might be on overall public health. This raises the question of who should pay for these trials. With regard to drugs and devices, industry representatives may think that they have already fulfilled their role in getting a drug to the registration stage. Perhaps the best solution would be joint industry-governmental funding.

Some trials, by virtue of their context and the intervention studied, are more pragmatic than others. Trials that test a low-cost intervention, pose few risks to participants, or are applied at a cluster level will almost automatically be more pragmatic in nature or easier to organize in a pragmatic fashion than will trials with high-cost, complex interventions. Health care systems with comprehensive electronic records or condition-specific registries offer excellent environments for pragmatic, low-cost trials.

The conflict between mechanistic trials and pragmatic trials is often expressed as the “greater internal validity of mechanistic studies” versus the “improved external validity of pragmatic trials.” Price et al.<sup>45</sup> describe two pragmatic trials designed to evaluate the real-world effectiveness of a leukotriene-receptor antagonist (LTRA) as compared with either an inhaled glucocorticoid for first-line asthma-controller therapy or a long-acting  $\beta_2$ -agonist (LABA) as add-on therapy in patients who were already receiving inhaled glucocorticoid therapy. The results at 2 months suggested that the LTRA was equivalent to an inhaled glucocorticoid as first-line controller therapy and was equivalent to a LABA as add-on therapy for diverse patients in primary care. Equivalence was not established at 2 years. Non-adherence to the prescribed regimen was a major limitation. To mimic real-world practice, the investigators constructed two treatment strategies that rapidly developed considerable similarity. This undercut the power of the trial to detect differences in the effectiveness of the drugs under investigation. The investigators noted that

“the very features of pragmatic trials that support the generalizability, or applicability, of their results to real-world practice may also reduce assay sensitivity and therefore limit the interpretation of results.” These features include heterogeneous populations of patients in which some of the patients may not have the condition of interest, along with a lack of blinding, absence of a placebo group, and suboptimal adherence to therapy.

A natural environment for clinical research might involve the integration of research and clinical practice through the development of “learning health care systems,” as advocated by the Institute of Medicine,<sup>46</sup> with relevant clinical and patient-reported outcome data collected by default. However, some have questioned whether this is feasible, given the clinical delivery pressures within today’s health care systems.<sup>47,48</sup>

Pragmatism should not be synonymous with a laissez-faire approach to trial conduct. The aim is to inform clinical practice, and that can be achieved only with high-quality trials. We believe that the concepts of internal and external validity and even the dichotomy between explanatory and pragmatic trials are overly simplistic. A better approach is to assess how a trial design adequately addresses the main objectives of the trial, including its ability to inform clinical practice.

---

## CONCLUSIONS

---

Some trials need not be forced to be pragmatic, and others will naturally have pragmatic features because of the nature of the intervention and the health care context in which the trials are conducted. Very few trials can be fully pragmatic. Trials of truly novel interventions can be game changers without being particularly pragmatic. No single trial, pragmatic or otherwise, is likely to answer all potential questions about the value of any health care technology. A pragmatic approach to pragmatism would be to adopt the features of pragmatic trials whenever feasible and sensible and when such features do not compromise trial quality and the ability to answer the clinical question of interest.

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

## REFERENCES

1. Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutical trials. *J Chronic Dis* 1967;20:637-48.
2. Developing and evaluating complex interventions: new guidance. London: Medical Research Council, 2008 ([www.mrc.ac.uk/documents/pdf/complex-interventions-guidance](http://www.mrc.ac.uk/documents/pdf/complex-interventions-guidance)).
3. Thorpe KE, Zwarenstein M, Oxman AD, et al. A Pragmatic-Explanatory Continuum Indicator Summary (PRECIS): a tool to help trial designers. *J Clin Epidemiol* 2009;62:464-75.
4. Roland M, Torgerson DJ. What are pragmatic trials? *BMJ* 1998;316:285.
5. Godwin M, Ruhland L, Casson I, et al. Pragmatic controlled clinical trials in primary care: the struggle between external and internal validity. *BMC Med Res Methodol* 2003;3:28.
6. Rothwell PM. External validity of randomised controlled trials: "to whom do the results of this trial apply?" *Lancet* 2005;365:82-93.
7. Devereaux PJ, Bhandari M, Clarke M, et al. Need for expertise based randomised controlled trials. *BMJ* 2005;330:88.
8. Ernst E, Canter PH. Limitations of "pragmatic" trials. *Postgrad Med J* 2005;81:203.
9. Treweek S, Zwarenstein M. Making trials matter: pragmatic and explanatory trials and the problem of applicability. *Trials* 2009;10:37.
10. Luce BR, Kramer JM, Goodman SN, et al. Rethinking randomized clinical trials for comparative effectiveness research: the need for transformational change. *Ann Intern Med* 2009;151:206-9.
11. Kent DM, Kitsios G. Against pragmatism: on efficacy, effectiveness and the real world. *Trials* 2009;10:48.
12. Eldridge S. Pragmatic trials in primary health care: what, when and how? *Fam Pract* 2010;27:591-2.
13. Patsopoulos NA. A pragmatic view on pragmatic trials. *Dialogues Clin Neurosci* 2011;13:217-24.
14. Ware JH, Hamel MB. Pragmatic trials — guides to better patient care? *N Engl J Med* 2011;364:1685-7.
15. Mitka M. FDA advisory decision highlights some problems inherent in pragmatic trials. *JAMA* 2011;306:1851-2.
16. Chalkidou K, Tunis S, Whicker D, Fowler R, Zwarenstein M. The role for pragmatic randomized controlled trials (pRCTs) in comparative effectiveness research. *Clin Trials* 2012;9:436-46.
17. Ratner J, Mullins D, Buesching DP, Cantrell RA. Pragmatic clinical trials: U.S. payers' views on their value. *Am J Manag Care* 2013;19(5):e158-65.
18. Kim SYH, Miller FG. Informed consent for pragmatic trials — the integrated consent model. *N Engl J Med* 2014;370:769-72.
19. Sugarman J, Califf RM. Ethics and regulatory complexities for pragmatic clinical trials. *JAMA* 2014;311:2381-2.
20. Yusuf S, Collins R, Peto R. Why do we need some large, simple randomized trials? *Stat Med* 1984;3:409-22.
21. Anderson ML, Griffin J, Goldkind SF, et al. The Food and Drug Administration and pragmatic clinical trials of marketed medical products. *Clin Trials* 2015;12:511-9.
22. Loudon K, Treweek S, Sullivan F, Donnan P, Thorpe KE, Zwarenstein M. The PRECIS-2 tool: designing trials that are fit for purpose. *BMJ* 2015;350:h2147.
23. Zwarenstein M, Treweek S, Gagnier JJ, et al. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. *BMJ* 2008;337:a2390.
24. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. *Lancet* 2002;360:7-22.
25. Roberts I, Yates D, Sandercock P, et al. Effect of intravenous corticosteroids on death within 14 days in 10008 adults with clinically significant head injury (MRC CRASH trial): randomised placebo-controlled trial. *Lancet* 2004;364:1321-8.
26. Fröbert O, Lagerqvist B, Olivecrona GK, et al. Thrombus aspiration during ST-segment elevation myocardial infarction. *N Engl J Med* 2013;369:1587-97.
27. Choudhry NK, Avorn J, Glynn RJ, et al. Full coverage for preventive medications after myocardial infarction. *N Engl J Med* 2011;365:2088-97.
28. Pickard R, Lam T, MacLennan G, et al. Antimicrobial catheters for reduction of symptomatic urinary tract infection in adults requiring short-term catheterisation in hospital: a multicentre randomised controlled trial. *Lancet* 2012;380:1927-35.
29. Califf RM, Sugarman J. Exploring the ethical and regulatory issues in pragmatic clinical trials. *Clin Trials* 2015;12:436-41.
30. Campbell R, Starkey F, Holliday J, et al. An informal school-based peer-led intervention for smoking prevention in adolescence (ASSIST): a cluster randomised trial. *Lancet* 2008;371:1595-602.
31. ClinicalTrials.gov. High-sensitivity troponin in the evaluation of patients with acute coronary syndrome (High-STEACS) trial (<https://clinicaltrials.gov/ct2/show/NCT01852123>).
32. Hussey MA, Hughes JP. Design and analysis of stepped wedge cluster randomized trials. *Contemp Clin Trials* 2007;28:182-91.
33. Treweek S, Lockhart P, Pitkethly M, et al. Methods to improve recruitment to randomised controlled trials: Cochrane systematic review and meta-analysis. *BMJ Open* 2013;3.
34. Relton C, Torgerson D, O' Cathain A, Nicholl J. Rethinking pragmatic randomised controlled trials: introducing the "cohort multiple randomised controlled trial" design. *BMJ* 2010;340:c1066.
35. McFadden E, Bashir S, Canham S, et al. The impact of registration of clinical trials units: the UK experience. *Clin Trials* 2015;12:166-73.
36. Hansson L, Hedner T, Dahlöf B. Prospective Randomized Open Blinded endpoint (PROBE) study: a novel design for intervention trials. *Blood Press* 1992;1:113-9.
37. Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. *Lancet* 2005;366:895-906.
38. The SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. *N Engl J Med* 2015;373:2103-16.
39. Simon GE, VonKorff M, Heiligenstein JH, et al. Initial antidepressant choice in primary care: effectiveness and cost of fluoxetine vs tricyclic antidepressants. *JAMA* 1996;275:1897-902.
40. The West of Scotland Coronary Prevention Study Group. Computerised record linkage: compared with traditional patient follow-up methods in clinical trials and illustrated in a prospective epidemiological study. *J Clin Epidemiol* 1995;48:1441-52.
41. Barry SJ, Dinnett E, Kean S, Gaw A, Ford I. Are routinely collected NHS administrative records suitable for endpoint identification in clinical trials? Evidence from the West of Scotland Coronary Prevention Study. *PLoS ONE* 2013;8(9):e75379.
42. Ford I, Murray H, Packard CJ, Shepherd J, Macfarlane PW, Cobbe SM. Long-term follow-up of the West of Scotland Coronary Prevention Study. *N Engl J Med* 2007;357:1477-86.
43. McConnachie A, Walker A, Robertson M, et al. Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study. *Eur Heart J* 2014;35:290-8.
44. PROMIS (<http://www.healthmeasures.net/explore-measurement-systems/promis>).
45. Price D, Musgrave SD, Shephstone L, et al. Leukotriene antagonists as first-line or add-on asthma-controller therapy. *N Engl J Med* 2011;364:1695-707.
46. Institute of Medicine. The learning healthcare system: workshop summary. Washington, DC: National Academies Press, 2007.
47. Vickers AJ. Clinical trials in crisis: four simple methodologic fixes. *Clin Trials* 2014;11:615-21.
48. Califf RM. Commentary on Vickers. *Clin Trials* 2014;11:626-7.

Copyright © 2016 Massachusetts Medical Society.